1. Copyright © 2005 American Medical Association. All rights reserved.
From: Low-Dose Bexarotene and Low-Dose Interferon Alfa-2b for Adult T-Cell Leukemia/Lymphoma Associated With Human T-Lymphotropic Virus 1
Arch Dermatol. 2005;141(3): doi: /archpedi
Figure Legend:
Increased apoptosis in the patient’s peripheral blood mononuclear cells (PBMCs) following a 96-hour in vitro exposure to bexarotene, interferon alfa-2b, and a combination of bexarotene and interferon alfa-2b. Prior to therapy, the patient’s PBMCs were isolated and treated in vitro with diluent, bexarotene (10 μmol/L), interferon alfa-2b (1000 U/mL), or a combination of bexarotene (10 μmol/L) and interferon alfa-2b (1000 U/mL). Both bexarotene and interferon alfa-2b alone induced increased apoptosis of the patient’s cells compared with diluent-treated cells. Combination treatment with both bexarotene and interferon alfa-2b yielded a higher level of apoptosis than either individual treatment, but no synergy was appreciated.
Date of download: 11/4/2017
Copyright © 2005 American Medical Association. All rights reserved.

2. Copyright © 2005 American Medical Association. All rights reserved.
From: Low-Dose Bexarotene and Low-Dose Interferon Alfa-2b for Adult T-Cell Leukemia/Lymphoma Associated With Human T-Lymphotropic Virus 1
Arch Dermatol. 2005;141(3): doi: /archpedi
Figure Legend:
Increased apoptosis in the patient’s peripheral blood mononuclear cells (PBMCs) following 96-hour in vitro exposure to bexarotene. Prior to therapy, the patient’s PBMCs were isolated and treated in vitro with diluent or bexarotene (10 μmol/L) and compared with the healthy volunteer’s PBMCs. The diluent-treated PBMCs of the healthy volunteer demonstrated 11.1% apoptosis, and the patient’s PBMCs demonstrated 17.9% apoptosis. With bexarotene treatment, the percentage of apoptotic cells in the patient’s PBMCs more than doubled, whereas the percentage in the healthy volunteer’s PBMCs did not change. CTCL indicates cutaneous T-cell lymphoma; HTLV-1, human T-lymphotopic virus 1.
Date of download: 11/4/2017
Copyright © 2005 American Medical Association. All rights reserved.

3. Copyright © 2005 American Medical Association. All rights reserved.
From: Low-Dose Bexarotene and Low-Dose Interferon Alfa-2b for Adult T-Cell Leukemia/Lymphoma Associated With Human T-Lymphotropic Virus 1
Arch Dermatol. 2005;141(3): doi: /archpedi
Figure Legend:
Using flow cytometry, we found a decreased tumor burden in peripheral blood mononuclear cells during treatment with low-dose bexarotene and interferon alfa-2b. Two months after starting therapy, the CD4/CD8 ratio decreased from 7.4 to within normal limits (shaded bars) in the patient’s peripheral blood mononuclear cells. The serum lactate dehydrogenase (LDH) levels also normalized (solid line).
Date of download: 11/4/2017
Copyright © 2005 American Medical Association. All rights reserved.

4. Copyright © 2005 American Medical Association. All rights reserved.
From: Low-Dose Bexarotene and Low-Dose Interferon Alfa-2b for Adult T-Cell Leukemia/Lymphoma Associated With Human T-Lymphotropic Virus 1
Arch Dermatol. 2005;141(3): doi: /archpedi
Figure Legend:
Marked decrease in axillary lymphadenopathy (arrows) during treatment with low-dose bexarotene and interferon alfa-2b. Helical computed tomographic scan of the chest with intravenous contrast at baseline (A) and 3 months after starting therapy (B).
Date of download: 11/4/2017
Copyright © 2005 American Medical Association. All rights reserved.

5. Copyright © 2005 American Medical Association. All rights reserved.
From: Low-Dose Bexarotene and Low-Dose Interferon Alfa-2b for Adult T-Cell Leukemia/Lymphoma Associated With Human T-Lymphotropic Virus 1
Arch Dermatol. 2005;141(3): doi: /archpedi
Figure Legend:
Resolution of patient’s erythroderma during treatment with low-dose bexarotene and interferon alfa-2b. Erythroderma of the trunk at baseline (A) and 2 months after starting therapy (B).
Date of download: 11/4/2017
Copyright © 2005 American Medical Association. All rights reserved.